Drugs / HR20013
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06554184 | Sep 2024 → Jul 2025 | chemotherapy-induced toxicity | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05509634 | Sep 2022 → Jun 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR20013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06554184 ↗ |
| Modality | Other / unclassified | “novel fixed-dose intravenous antiemetic combination” PMID 39621965 ↗ Dec 2024 |
| Route | Intravenous | “novel fixed-dose intravenous antiemetic combination” PMID 39621965 ↗ Dec 2024 |